Possible strategy for cancer treatment found in nuclear transport proteins

December 17, 2019

Although less often the focus of cancer research, recent studies have hinted at the possible importance of a type of protein known as nuclear transport receptors. Now researchers at Kanazawa University and collaborating institutions in Japan and the US have identified a nuclear transport receptor protein that plays a key role in processes that sustain aggressive head and neck cancers, as well as some of the mechanisms behind these processes.

"Current gene expression network approaches commonly focus on TFs [transcription factors], biasing network-based discovery efforts away from potentially important non-TF proteins," point out Masaharu Hazawa and Richard Wong and their colleagues in the report of their latest results. Taking a different tack, they noted that although abnormalities in nuclear transport receptors and their significance in the progression of cancer were not yet understood, recent studies had identified the importance of a type of nuclear transport receptor named karyopherin-α (KPNA)/importin-α in cell differentiation, whereby immature cells acquire the characteristics and functions of specific mature cell types. Tumors of non-differentiated cells are widely understood to be more aggressive.

Noting the role of KPNA in cell fate determination, Hazawa, Wong and colleagues re-analysed the Cancer Genome Atlas, which identified KPNA4 as most higly expressed subtype of KPNAs in head and neck squamous cancer cells (HNSCCs). Using a green fluorescent protein that had a nuclear localization signal, the researchers then investigated the role of KPNA4. They showed that while this green fluorescent protein would normally then localize in the nucleus, in HNSCCs where they had "knocked down" the gene expressing KPNA4 (so that the protein KPNA4 was not expressed) high levels of the green fluorescent protein remained in the cytoplasm instead. As well as the impact on nuclear transport of molecules with the nuclear localization signal, the researchers were also able to observe how silencing the KPNA4 expressing gene reduced the "cell proliferation, migration ability and resistance to radiation" in HNSCCs.

Further studies revealed not only the role of KPNA4 in repressing differentiation of epithelial cells, but also important transcription factors and signaling pathways controlled by KPNA4-dependent nuclear import systems. In their report the researchers conclude, "Taken together, these results indicate that targeting disease-specifically altered transport systems may serve as promising therapeutic strategies for cancer treatment."

Head and neck squamous cell carcinoma

Squamous cell carcinomas are a non-melanoma type of skin cancer, which are the 5th most commonly occurring cancers worldwide. It is a disease that affects the squamous epithelium - flat cells found lining the skin and mucous membranes. Head and neck squamous cancer affects the mucous cells in the mouth, nose and throat.

Transcription factors

Transcription factors read and interpret the genetic code in cells. They bind to specific sequences of DNA and control the rate of transcription of that genetic code to messenger RNA, which then conveys that genetic information in the synthesis of new proteins. A number of cancer-suppressing transcription factors have already been identified.

Nuclear transport receptors

While small molecules can move relatively freely across the cell membrane, larger molecules such as proteins need nuclear transport receptors such as karyopherins/importins to enter or leave the cell. Karyopherins help macromolecules navigate the nuclear pore complexes that act as the gateway to the cell.


In a complex organism like a human most cells undergo several differentiations from the initial immature cell into more specialized mature cells that often have very different structures and functions. The process generally involves the activation of a dormant transcription factor.

Hazawa, Wong and colleagues noticed lower levels of KPNA4 where epithelial differentiation increased. Further tests identified that a particular protein regulated by KPNA4 is ras-responsive binding protein (RREB1), and that the Ras/MAPK signaling was affected. Previous work had already established the role of RREB1 in oncogenic Ras/MAPK signaling. Hazawa, Wong and colleagues found that KPNA4 activates a pathway based on Ras and MAPK proteins by mediating nuclear-transport of the Ras-responsive element-binding protein (RREB1). Furthermore, they identified MAPK-dependent processes that enhance transport activity of KPNA4, in what they describe as a "feed forward" process.

Kanazawa University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.